Adult Cardiology > Elixir Medical Corporation > DESyne® BD NOVOLIMUS™ Eluting Coronary Stent System
The Elixir DESyne BD Novolimus-Eluting Coronary Stent System represents a significant advancement in biodegradable coating technology, eliminating the need for a primer coating and achieving a bare metal surface within 6 -9 months, while providing excellent DES results.
The DESyne BD stent is manufactured on a clinically-proven cobalt chromium platform to maximize deliverability.
Lowest profile stent design with ultra-thin struts (81 microns) for high flexibility and deliverability
Substantial vessel wall coverage for uniform drug delivery and open cell design for ease of side branch access
Ultra-thin biodegradable polymer dissolves within 6-9 months
Trusted polylactide-based polymer
Sustainable performance with lower drug dose
Clinically proven 'olimus' drug family
Active metabolite of Sirolimus
Potent anti-proliferative agent
Elixir conducted five separate trials which included over 400 patients for the prevention of restenosis using DESyne and DEsyne BD stent systems resulting in excellent and sustained safety and effectiveness clinical outcomes.
Elixir Medical has completed the EXCELLA BD randomized trial for the DESyne BD Novolimus-Eluting Stent System.
The EXCELLA BD Trial was a randomized, prospective, multicenter, single-blind, non-inferiority study evaluating the DESyne® BD Novolimus Eluting Coronary Stent System (CSS) with resorbable polylactide-based polymer compared to the Endeavor Zotarolimus Eluting Coronary Stent System.